Vulnerability of positron emission tomography radiotracers to endogenous competition: New insights

Quarterly Journal of Nuclear Medicine

Volumn 45, Issue 2, 2001, Pages 124-138

  Laruelle, M ^a   Huang, Y ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Brain; Dopamine; Radiopharmaceuticals; Receptors, dopamine D2; Tomography, emission computed; Tomography, emission computed, single photon

Indexed keywords

3 METHYLSPIPERONE; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; APO; CARBON 11; CITALOPRAM; CLEBOPRIDE; DOPAMINE; DOPAMINE 2 RECEPTOR; EPIDEPRIDE; FALLYPRIDE; FLUORINE 18; IBF; IODINE 123; IODINE 125; ISOREMOXIPRIDE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROTRANSMITTER; NMSP; NPA; PIMOZIDE; RACLOPRIDE; RADIOLIGAND; SKF 82957; SPIPERONE; SPIPERONE DERIVATIVE; TRACER; TRITIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING COMPETITION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; LIGAND BINDING; MOLECULAR INTERACTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPTIC TRANSMISSION;

ANIMALS; BENZAMIDES; BRAIN; DOPAMINE; HUMANS; PYRROLIDINES; RACLOPRIDE; RECEPTORS, DOPAMINE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034945024     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (151)

1. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review
2. In vivo binding of N-n-propylnorapomorphine in the rat brain: Regional localization, quantification in striatum and lack of correlation with dopamine metabolism
3. 3H](-)-N-n-propylnorapomorphine in the mouse brain
4. 3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors
5. Synthesis and in vivo distribution in the rat of a dopamine agonist: N- ([11C]methyl)norapomorphine
6. Kinetic properties of the in vivo accumulation of the dopamine D-2 receptor antagonist raclopride in the mouse brain in vivo
7. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride
8. Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine
9. 3H]raclopride binding in the rat brain
10. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography
11. Distinct binding patterns of [3H]raclopride and [3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for pet studies
12. Effect of acute endogenous dopamine depletion on in vivo [123I]IBZM binding in rodents
13. Nicotine-induced dopamine release evaluated with in vivo 3H raclopride binding studies: Comparison with in vivo dialysis data
14. Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: Iodobenzamide and iodoethylspiperone
15. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography
16. Sensitivity of binding of high-affinity dopamine receptor radioligands to increased synaptic dopamine
17. In vivo receptor binding: Attempts to improve specific/non-specific ratios
18. Exogenous 1-dopa alters spiroperidol binding, in vivo, in the mouse striatum
19. In vivo [3H]spiperone binding: Evidence for accumulation in corpus striatum by agonist-mediated receptor internalization
20. Endogenous dopamine (DA) modulates [3H]spiperone binding in vivo in rat brain
21. Effects of haloperidol and d-amphetamine on in vivo 3H-spiroperiodol binding in the rat forebrain
22. Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment
23. 3H]raclopride: Implications for positron emission tomography of the human brain
24. Effects of the GABAergic system on in vivo binding of [3H]N-methylspiperone
25. In vivo binding of 3H-pimozide in mouse striatum: Effects of dopamine agonists and antagonists
26. In vivo evaluation of R/S/[C-11]SKF 82957 in rats as D-1 agonist tracer for PET: Effect of endogenous dopamine and chronic D-1 and D-2 antagonist
27. The effect of benzodiazepines on the binding of [3H]SCH 23390 in vivo
28. An increase in the in vivo binding of [3H]SCH 23390 induced by MK-801 in the mouse striatum
29. Development of muscarinic cholinergic receptor ligands with various affinities for receptors
30. Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors
31. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography
32. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis
33. Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine
34. Effect of reserpine-induced depletion of synaptic dopamine on [C-11]raclopride binding to D-2-dopamine receptors in the monkey brain
35. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
36. Difference in response of D2 receptor binding between 11C-N-methylspiperone and 11C-raclopride against anesthetics in rhesus monkey brain
37. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion
38. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
39. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography
40. PET measurement of endogenous neurotransmitter activity using high and low affinity radiotracers
41. Effect of anesthetics and evoked dopamine release on [11C]raclopride binding in the cat striatum
42. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continous infusion PET scans
43. Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates
44. Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain
45. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756
46. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys
47. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum
48. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: Multiparametric PET studies combined with microdialysis analysis
49. Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: Positron emission tomography studies with microdialysis in the conscious monkey brain
50. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates
51. 123I]IBZM binding to the D2 receptor in non-human primates
52. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine
53. Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release
54. Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors
55. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study
56. Positron Emission Tomography (PET) studies of dopamine/cholinergic interaction in the baboon brain
57. 18F]N-methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons
58. Ketamine increases the striatal N-[11C]methylspiperone binding in vivo: Positron emission tomography study using conscious rhesus monkey
59. PET studies of binding competition between endogenous dopamine and D1 antagonists and agonists
60. A PET study of D1-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain
61. Amphetamine induced decrease in [18F]-N-methylspiperidol binding in the baboon brain using positron emission tomography (PET)
62. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects
63. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
64. 11C]raclopride in the human brain
65. PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects
66. Evidence for striatal dopamine release during a video game
67. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects
68. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - A PET study with [11C]raclopride
69. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors
70. Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans
71. PET imaging of amphetamine-induced endogenous dopamine release in mesolimbic and nigro-striatal dopamine systems in humans
72. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain
73. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
74. Imaging D-2 receptor occupancy by endogenous dopamine in humans
75. SPECT imaging of striatal dopamine release after amphetamine challenge
76. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography
77. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans
78. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans
79. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls
80. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
81. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis
82. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
83. Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine
84. On the preferential release of dopamine in the nucleus accumbens by amphetamine: Further evidence obtained by vertically implanted concentric dialysis probes
85. Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo
86. Reproducibility of repeated measures of endogenous dopamine competition with [11C]raclopride in the human brain in response to methylphenidate
87. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects
88. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
89. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
90. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
91. Reduced amphetamine-stimulated dopamine release in cocaine addicts as measured by [123I]IBZM SPECT
92. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients
93. Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression
94. Increased dopamine transmission in schizophrenia: Relationship to illness phases
95. Dopamine D2 receptor binding sites for agonists. A tetrahedral model
96. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain
97. Dopamine D-2 receptor imaging radiopharmaceuticals: Synthesis, radiolabeling, and in vitro binding of R-(+)- and S-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide
98. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent
99. Fluorinated benzamide neuroleptics - III. Development of (S)-N-[(1-allyl- 2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer
100. Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors
101. [123I] Labeled epidepride SPECT studies of dopamine D2 receptors in man
102. Spiperone: A ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding
103. 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex
104. A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum
105. (+-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benza zepine, a new high affinity D1 dopamine receptor ligand: Synthesis and structure-activity relationship
106. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum
107. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists
108. Effects of solvation on the ionization and conformation of raclopride and other antidopaminergic 6-methoxysalicylamides: Insight into the pharmacophore
109. Aromatic and amine substituent effects on the apparent lipophilicities of N-[(2-pyrrolidinyl)methyl]-substituted benzamides
110. 2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides
111. An admonition when measuring the lipophilicity of radiotracers using counting techniques
112. Optimal conditions for [3H]apomorphine binding and anomalous equilibrium binding of [3H]apomorphine and [3H]spiperone to rat striatal membranes: Involvement of surface phenomena versus multiple binding sites
113. Effect of N-alkylation on the affinities of analogues of spiperone for dopamine D2 and serotonin 5-HT2 receptors
114. The relative dependence of calcium antagonists and neuroleptics binding to brain and heart receptors on drug lipophilicity
115. 50) of an enzymatic reaction
116. Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands
117. Opiate antagonist receptor binding in vivo: Evidence for a new receptor binding model
118. Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters
119. Quantitative in vivo receptor binding I. Theory and application to the muscarinic cholinergic receptor
120. SPECT quantification of [1231]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters
121. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers
122. Kinetic modeling of [C-11]raclopride: Combined PET-microdialysis studies
123. G protein-coupled receptor adaptation mechanisms
124. The role of receptor kinases and arrestins in G protein-coupled receptor regulation
125. Role of endocytosis in mediating downregulation of G-protein-coupled receptors
126. Agonist-induced desensitization of dopamine D1 receptor-stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization
127. Dopamine D1 receptor distribution in Sf9 cells imaged by confocal microscopy: A quantitative evaluation
128. Agonist-induced morphological decrease in cellular D1A dopamine receptor staining
129. Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells
130. Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes
131. Agonist stimulation provokes dendritic and axonal dopamine D(1) receptor redistribution in primary cultures of striatal neurons
132. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists
133. Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice
134. Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5
135. 2 dopamine receptors in human Y-79 retinoblastoma cells
136. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells
137. Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration
138. Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors
139. Visualization of antipsychotic drug binding to living mesolimbic neurons reveals D2 receptor, acidotropic, and lipophilic components
140. Sodium-dependent interaction of benzamides with dopamine receptors
141. 3H]raclopride to rat and human brain membranes
142. Kinetic evidence for isomerization of the dopamine receptors-raclopride complex
143. Evidence for the importance of a carboxyl group in the binding of ligands to the D2 dopamine receptor
144. Regulation of dopamine D2 receptors by sodium and pH
145. pH dependence of sulpiride binding to D2 dopamine receptors in bovine brain
146. pH dependence of ligand binding to D2 dopamine receptors
147. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: Control and competition studies
148. Dopamine D2 receptor mediated regulation of central cholinergic activity: PET studies with [18F]fluoroepibatidine
149. Dopamine receptor-mediated regulation of striatal cholinergic activity: Positron emission tomography studies with norchloro[18F]fluoroepibatidine
150. 11C]methylphenidate to the dopamine transporter in vivo: Insensitivity to synaptic dopamine
151. Kinetic derivation of serotonin 5HT-1A receptor binding potential with [11C]carbonyl-way 100635 and competition studies with endogenous serotonin